Open Access iconOpen Access

ARTICLE

MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression

CHENG-GONG LUO1,2,#, JIAO ZHANG1,#, YUN-ZHAO AN1, XUAN LIU1, SHUAI-JIE LI1, WEI ZHANG1, KAI LI1, XU ZHAO1, DONG-BO YUAN1, LING-YUE AN1, WEI CHEN2, YE TIAN1,*, BIN XU1,*

1 Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, China
2 Department of Urology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

* Corresponding Authors: YE TIAN. Email: email; BIN XU. Email: email
# These authors contributed equally to this work

(This article belongs to the Special Issue: Advances in Biomarker Research: Unveiling the Pathways to Precision Medicine)

BIOCELL 2024, 48(5), 771-792. https://doi.org/10.32604/biocell.2024.048878

Abstract

Background: Ferroptosis, a lipid peroxidation-mediated programmed cell death, is closely linked to tumor development, including prostate cancer (PCa). Despite established connections between ferroptosis and PCa, a comprehensive investigation is essential for understanding its impact on patient prognosis. Methods: A risk model incorporating four ferroptosis-related genes was developed and validated. Elevated risk scores correlated with an increased likelihood of biochemical recurrence (BCR), diminished immune infiltration, and adverse clinicopathological characteristics. To corroborate these results, we performed validation analyses utilizing datasets from both the Cancer Genome Atlas Cohort (TCGA) and the Gene Expression Synthesis Cohort (GEO). Moreover, we conducted further investigations into the pivotal gene identified in our model to explore its impact on tumor characteristics through cell proliferation and invasion assays, as well as animal studies conducted in vivo. Additionally, we conducted further experiments involving ferroptosis-related analysis to validate its association with ferroptosis. Results: The risk model demonstrated exceptional predictive capabilities for prognosis and therapeutic outcomes in PCa patients. Mitogen-activated protein kinase 9 (MAPK9) emerged as a crucial gene within the model. In vivo and in vitro experiments explored MAPK9’s role in ferroptosis and its influence on tumor migration and proliferation. Conclusion: The findings provide a novel perspective for advancing ferroptosis exploration in PCa, bridging basic research and clinical applications.

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

APA Style
LUO, C., ZHANG, J., AN, Y., LIU, X., LI, S. et al. (2024). MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression. BIOCELL, 48(5), 771-792. https://doi.org/10.32604/biocell.2024.048878
Vancouver Style
LUO C, ZHANG J, AN Y, LIU X, LI S, ZHANG W, et al. MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression. BIOCELL . 2024;48(5):771-792 https://doi.org/10.32604/biocell.2024.048878
IEEE Style
C. LUO et al., "MAPK9 as a therapeutic target: unveiling ferroptosis in localized prostate cancer progression," BIOCELL , vol. 48, no. 5, pp. 771-792. 2024. https://doi.org/10.32604/biocell.2024.048878



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 399

    View

  • 147

    Download

  • 0

    Like

Share Link